Prevalence and quantity of circulating tumor cells (CTCs) after adjuvant chemotherapy in patients with HER2-negative early breast cancer (EBC).
Fabienne Schochter
Research Funding - Veridex
Ulrich Andergassen
No relevant relationships to disclose
Julia Katharina Neugebauer
No relevant relationships to disclose
Thomas W. P. Friedl
No relevant relationships to disclose
Aurelia Pestka
No relevant relationships to disclose
Julia Kathrin Jueckstock
No relevant relationships to disclose
Bernadette Jaeger
Honoraria - Novartis; Veridex
Research Funding - Veridex
Other Remuneration - Novartis
Jessica Christine Salmen
No relevant relationships to disclose
Philip Gm Hepp
No relevant relationships to disclose
Georg Heinrich
No relevant relationships to disclose
Oumar Camara
No relevant relationships to disclose
Thomas Decker
No relevant relationships to disclose
Angelika Ober
No relevant relationships to disclose
Tanja N. Fehm
Research Funding - Novartis
Klaus Pantel
Research Funding - Veridex
Peter A. Fasching
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Amgen; Novartis
Andreas Schneeweiss
Consultant or Advisory Role - Lilly; Sanofi
Honoraria - Lilly; Sanofi
Research Funding - Lilly; Sanofi
Matthias W. Beckmann
No relevant relationships to disclose
Wolfgang Janni
Consultant or Advisory Role - Veridex
Research Funding - Veridex
Expert Testimony - Veridex
Brigitte Kathrin Rack
Research Funding - Veridex